Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, Teixeira HD, Jemec GB. Kimball AB, et al. Among authors: sobell jm. J Eur Acad Dermatol Venereol. 2016 Jun;30(6):989-94. doi: 10.1111/jdv.13216. Epub 2015 Jul 22. J Eur Acad Dermatol Venereol. 2016. PMID: 26201313 Free PMC article. Clinical Trial.
Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
Leonardi C, Sobell JM, Crowley JJ, Mrowietz U, Bao Y, Mulani PM, Gu Y, Okun MM. Leonardi C, et al. Among authors: sobell jm. Br J Dermatol. 2012 Sep;167(3):658-67. doi: 10.1111/j.1365-2133.2012.11041.x. Epub 2012 Aug 20. Br J Dermatol. 2012. PMID: 22564148 Clinical Trial.
Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM. Strober BE, et al. Among authors: sobell jm. Br J Dermatol. 2012 Dec;167(6):1374-81. doi: 10.1111/bjd.12000. Epub 2012 Nov 2. Br J Dermatol. 2012. PMID: 22897348 Clinical Trial.
Update on TNF Inhibitors in Dermatology.
Sobell JM. Sobell JM. Semin Cutan Med Surg. 2016 Jun;35(6 Suppl):S104-6. doi: 10.12788/j.sder.2016.033. Semin Cutan Med Surg. 2016. PMID: 27537073
29 results